Evidence map›Paper›PMID 32986383›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2020

Cross-Protective IgG and IgA Antibodies against Oncogenic and Non-Oncogenic HPV Genotypes.

Ana Paula Costa, Paulo César Giraldo, Ricardo Ney Cobucci, Márcia Lopes Consolaro, Raquel Pantarotto Souza, Luanda Barbara Canário, Paula Renata Machado, Rand Randall Martins, Pedro Vieira Baptista, José Eleutério Jr and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. The role and mechanism of human papillomavirus in urinary system tumors.The Journal of international medical research · 2025
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Ana Paula CostaPostgraduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, Brazil.
Paulo César GiraldoDepartment of Gynecology, and Obstetrics, State University of Campinas, Campinas, Brazil.
Ricardo Ney CobucciPostgraduate Program in Biotechnology, Potiguar University, Natal, Brazil.
Márcia Lopes ConsolaroClinical Cytology and STD Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, PR, Brazil.
Raquel Pantarotto SouzaClinical Cytology and STD Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, PR, Brazil.
Luanda Barbara CanárioDepartment of Clinical Analysis and Toxicology, Federal University of Rio Grande do Norte, Natal, Brazil.
Paula Renata MachadoDepartment of Clinical Analysis and Toxicology, Federal University of Rio Grande do Norte, Natal, Brazil.
Rand Randall MartinsDepartment of Pharmacy, Federal University of Rio Grande do Norte, Natal, Brazil.
Pedro Vieira BaptistaHospital Lusíadas Porto and Unidade de Tracto Genital Inferior, Serviço de Ginecologia e Obstetrícia, Centro Hospitalar de São João, Porto, Portugal.
José Eleutério JrDepartment of Female, Child and Adolescent Health, Federal University of Ceará, Fortaleza, Brazil.
Ana Katherine GonçalvesPostgraduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, Brazil.ORCID 0000-0002-8351-5119
Universidade Federal do Rio Grande do Norte · BRUniversidade Estadual de Maringá · BRHospital de São João · PTUniversidade Potiguar · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe aim of the study was to describe the course of IgG/IgA immune response in women immunized with bivalent vaccine and in women non-vaccinated with HPV infection, as well as evaluating the cross-protection against non-vaccine HPV types.

methodsSerum and cervical mucus samples were collected from infected and vaccinated women for HPV detection/genotyping and for detection of IgG/IgA anti-HPV/VLP (Virus-like Particles) by ELISA.

resultsThe median absorbance detected in serum samples for anti-HPV-IgG antibodies was higher in vaccinated women when compared to HPV infected women (p <0.01), however, the median absorbance in cervical mucus samples for anti-HPV-IgA was higher in infected women when compared to vaccinated women (p <0.01). Additionally, our analyses also provided additional evidence for cross-protective efficacy of the HPV-16/18 vaccine against HPV-82, -6, -11, -13, -61, -72 and -74.

conclusionThe IgG antibodies were significantly more detected in the serum of vaccinated women, while the IgA was found in greater quantities in cervical samples from those infected by the virus. In addition, there is evidence that the bivalent vaccine provides cross-protection against other non-oncogenic viral subtypes.<br />.

Indexed as

Antibodies, ViralCase-Control StudiesCervix UteriFemaleFollow-Up StudiesGenotypeHumansImmunoglobulin AImmunoglobulin GPapillomaviridaePapillomavirus InfectionsPrognosisProspective StudiesUterine Cervical DysplasiaUterine Cervical NeoplasmsVaccinationAntibodies, ViralImmunoglobulin AImmunoglobulin GCross ProtectionHPVimmunoglobulin AImmunoglobulin GVaccine

Identifiers

PMID32986383
PMCPMC7779425
OpenAlexW3090500980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.